These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Recent advances in drug delivery systems for treating ocular complications of systemic diseases. Lee SS; Hughes PM; Robinson MR Curr Opin Ophthalmol; 2009 Nov; 20(6):511-9. PubMed ID: 19667987 [TBL] [Abstract][Full Text] [Related]
6. Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies. Nguyen QD; Merrill PT; Sepah YJ; Ibrahim MA; Banker A; Leonardi A; Chernock M; Mudumba S; Do DV Ophthalmology; 2018 Dec; 125(12):1984-1993. PubMed ID: 30060978 [TBL] [Abstract][Full Text] [Related]
7. The use of intraocular corticosteroids. Kiernan DF; Mieler WF Expert Opin Pharmacother; 2009 Oct; 10(15):2511-25. PubMed ID: 19761356 [TBL] [Abstract][Full Text] [Related]
8. Dexamethasone intravitreal implant: an effective adjunctive treatment for recalcitrant noninfectious uveitis. Miserocchi E; Modorati G; Pastore MR; Bandello F Ophthalmologica; 2012; 228(4):229-33. PubMed ID: 23038070 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Pavesio C; Zierhut M; Bairi K; Comstock TL; Usner DW; Ophthalmology; 2010 Mar; 117(3):567-75, 575.e1. PubMed ID: 20079922 [TBL] [Abstract][Full Text] [Related]
10. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma. Malone PE; Herndon LW; Muir KW; Jaffe GJ Am J Ophthalmol; 2010 May; 149(5):800-6.e1. PubMed ID: 20189158 [TBL] [Abstract][Full Text] [Related]
11. Intravitreal triamcinolone acetonide injection for the treatment of posterior uveitis. Ozkiris A Ocul Immunol Inflamm; 2006 Aug; 14(4):233-8. PubMed ID: 16911985 [TBL] [Abstract][Full Text] [Related]
12. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Jaffe GJ; Martin D; Callanan D; Pearson PA; Levy B; Comstock T; Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128 [TBL] [Abstract][Full Text] [Related]
13. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Nguyen QD; Callanan D; Dugel P; Godfrey DG; Goldstein DA; Wilensky JT Retina; 2006 Oct; Suppl():1-16. PubMed ID: 17050954 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal triamcinolone acetonide: a change in a paradigm. Jonas JB Ophthalmic Res; 2006; 38(4):218-45. PubMed ID: 16763379 [TBL] [Abstract][Full Text] [Related]
15. New developments in corticosteroid therapy for uveitis. Taylor SR; Isa H; Joshi L; Lightman S Ophthalmologica; 2010; 224 Suppl 1():46-53. PubMed ID: 20714181 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal steroids for macular edema: the past, the present, and the future. Cunningham MA; Edelman JL; Kaushal S Surv Ophthalmol; 2008; 53(2):139-49. PubMed ID: 18348879 [TBL] [Abstract][Full Text] [Related]
17. Pharmacologic and clinical profile of dexamethasone intravitreal implant. Robinson MR; Whitcup SM Expert Rev Clin Pharmacol; 2012 Nov; 5(6):629-47. PubMed ID: 23234323 [TBL] [Abstract][Full Text] [Related]